KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Regeneron Pharmaceuticals (REGN) EBITDA Margin (2016 - 2026)

Regeneron Pharmaceuticals (REGN) has disclosed EBITDA Margin for 18 consecutive years, with 18.35% as the latest value for Q1 2026.

  • For Q1 2026, EBITDA Margin fell 957.0% year-over-year to 18.35%; the TTM value through Mar 2026 reached 29.53%, down 316.0%, while the annual FY2025 figure was 32.0%, 42.0% up from the prior year.
  • EBITDA Margin hit 18.35% in Q1 2026 for Regeneron Pharmaceuticals, down from 21.96% in the prior quarter.
  • Across five years, EBITDA Margin topped out at 1659.2% in Q1 2022 and bottomed at 18.35% in Q1 2026.
  • Average EBITDA Margin over 5 years is 197.66%, with a median of 30.59% recorded in 2023.
  • Year-over-year, EBITDA Margin surged 161562bps in 2022 and then tumbled -163153bps in 2023.
  • Regeneron Pharmaceuticals' EBITDA Margin stood at 1233.4% in 2022, then crashed by -97bps to 36.56% in 2023, then plummeted by -39bps to 22.42% in 2024, then decreased by -2bps to 21.96% in 2025, then dropped by -16bps to 18.35% in 2026.
  • According to Business Quant data, EBITDA Margin over the past three periods came in at 18.35%, 21.96%, and 39.33% for Q1 2026, Q4 2025, and Q3 2025 respectively.